Md. Code, Health - General § 13-3502
This is the official text of Md. Code, Health - General § 13-3502, part of Maryland’s Code, Health - General — covers public health regulation.
Not legal advice. This page reproduces the official text of a government statute for reference only. Laws change, and how a statute applies depends on your specific facts. For advice about your situation, consult a licensed attorney in your state.
§13–3502.
Official statutory text
(a) The Secretary shall establish guidelines for the co–prescribing of opioid overdose reversal drugs that are applicable to all licensed health care providers in the State who are authorized by law to prescribe a monitored prescription drug, as defined in § 21–2A–01 of this article.
(b) The guidelines established under subsection (a) of this section shall address the co–prescribing of opioid overdose reversal drugs for patients who are:
(1) At an elevated risk of overdose; and
(2) (i) Receiving opioid therapy for chronic pain;
(ii) Receiving a prescription for benzodiazepines; or
(iii) Being treated for opioid use disorders.
(b) The guidelines established under subsection (a) of this section shall address the co–prescribing of opioid overdose reversal drugs for patients who are:
(1) At an elevated risk of overdose; and
(2) (i) Receiving opioid therapy for chronic pain;
(ii) Receiving a prescription for benzodiazepines; or
(iii) Being treated for opioid use disorders.
Status: in_force · Read it on the official government site
Need a lawyer in Maryland?
Find a Maryland lawyer
About this page: Statute text is reproduced from official government publishers via the
Open US Law dataset
(Vaquill AI, snapshot v2026.08, CC BY 4.0). Primary legislative text like this is public domain under the government-edicts doctrine
(Georgia v. Public.Resource.Org, 2020). We link every section back to its official source so you can verify it independently.